CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies

S. G. Holtan, W. J. Hogan, M. A. Elliott, S. M. Ansell, D. J. Inwards, L. F. Porrata, P. B. Johnston, I. N. Micallef, M. Q. Lacy, D. A. Gastineau, M. R. Litzow

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences